IL10 and colitis: This issue is manageable, however, given that patients who develop or did not develop colitis after anti-CTLA-4 therapy have distinct microbial communities [35], IL-10−/− mouse models show Bifidobacteria may prevent colitis after anti-CTLA-4 therapy [97], and FMT may prove effective [98].